FDA Approves Omalizumab for Reduction of Allergic Reactions in Patients with Food Allergies

FDA approves omalizumab (Xolair; Novartis) as the first and only medicine to reduce allergic reactions in patients with food allergies. The drug is not for emergency treatment and patients should continue avoiding allergenic foods. Positive results from the phase 3 OUtMATCH study show potential for omalizumab to mitigate allergic reactions in patients with multiple food allergies.